Arvinas starts patient dosing of protein degrader

Arvinas has announced the initiation of patient dosing in its second clinical program.

The Phase 1 clinical trial of ARV-471, an oral estrogen receptor (ER)-targeting PROTACĀ® protein degrader, will evaluate the safety, tolerability, and pharmacokinetics of ARV-471 in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer. more